Add to ORKGHuseyin Naci and Jonathan Cylus provide arguments for how to improve the regulation concerning pharmaceutical drugs. Since drugs are not assessed relative to alternatives on the market, they claim it becomes more difficult to accurately evaluate a drug’s successes and harms. Increased innovation and a more streamlined delivery of information are some of the benefits they attribute to more rigorous drug regulations
International audienceFewer than half of new drugs have data on their comparative benefits and harms...
Fewer than half of new drugs have data on their comparative benefits and harms against existing trea...
Fewer than half of new drugs have data on their comparative benefits and harms against existing trea...
Before a new drug can be marketed, the Food and Drug Administration must be satisfied that it is saf...
Before a new drug can be marketed, the Food and Drug Administration must be satisfied that it is saf...
New prescription drugs are developed and tested for quality, safety, and efficacy by the pharmaceuti...
Before a new drug can be marketed, the Food and Drug Administration must be satisfied that it is saf...
Fewer than half of new drugs have data on their comparative benefits and harms against existing trea...
International audienceFewer than half of new drugs have data on their comparative benefits and harms...
International audienceFewer than half of new drugs have data on their comparative benefits and harms...
International audienceFewer than half of new drugs have data on their comparative benefits and harms...
International audienceFewer than half of new drugs have data on their comparative benefits and harms...
International audienceFewer than half of new drugs have data on their comparative benefits and harms...
International audienceFewer than half of new drugs have data on their comparative benefits and harms...
International audienceFewer than half of new drugs have data on their comparative benefits and harms...
International audienceFewer than half of new drugs have data on their comparative benefits and harms...
Fewer than half of new drugs have data on their comparative benefits and harms against existing trea...
Fewer than half of new drugs have data on their comparative benefits and harms against existing trea...
Before a new drug can be marketed, the Food and Drug Administration must be satisfied that it is saf...
Before a new drug can be marketed, the Food and Drug Administration must be satisfied that it is saf...
New prescription drugs are developed and tested for quality, safety, and efficacy by the pharmaceuti...
Before a new drug can be marketed, the Food and Drug Administration must be satisfied that it is saf...
Fewer than half of new drugs have data on their comparative benefits and harms against existing trea...
International audienceFewer than half of new drugs have data on their comparative benefits and harms...
International audienceFewer than half of new drugs have data on their comparative benefits and harms...
International audienceFewer than half of new drugs have data on their comparative benefits and harms...
International audienceFewer than half of new drugs have data on their comparative benefits and harms...
International audienceFewer than half of new drugs have data on their comparative benefits and harms...
International audienceFewer than half of new drugs have data on their comparative benefits and harms...
International audienceFewer than half of new drugs have data on their comparative benefits and harms...
International audienceFewer than half of new drugs have data on their comparative benefits and harms...
Fewer than half of new drugs have data on their comparative benefits and harms against existing trea...
Fewer than half of new drugs have data on their comparative benefits and harms against existing trea...